tirzepatide surmount 5 surmount-1 weight loss nondiabetic non-diabetic obesity trial For the first time, and semaglutide were put in the same trial. SURMOUNT-5. Phase 3b RCT. 751 adults Tirzepatide after intensive lifestyle intervention – Tirzepatide (Zepbound; Eli Lilly and

Erectile dysfunction may signal underlying cardiovascular disease and should prompt comprehensive cardiovascular risk assessment using tools like QRISK3

Same active ingredient, three different paths to get it

A cohort study result indicates that weekly doses of 1.7 mg and 2.4 mg of semaglutide led to weight loss comparable to that observed in randomized clinical trials

Keeping a simple injection diary or using a smartphone app can help patients track their rotation pattern, particularly important for those using multiple injectable medications

Its an effective solution for those feeling mentally foggy or low on energy